title: [Comparison of therapeutic effects between acupoint-injection and intramuscular-injection of Bacillus Calmette-Guerin polysaccharide nucleic acid for bronchial asthma].
abstract: OBJECTIVE
  To observe the curative effect of acupoint-injection and intramuscular-injection of Bacillus Calmette-Guerin (BCG) Polysaccharide Nucleic Acid for bronchial asthma.
  
  
  METHODS
  Sixty patients with bronchial asthma were equally randomized into acupoint-injection group and intramuscular-injection group. For patients of the acupoint-injection group, 2 mL of BCG was injected into bilateral Feishu (BL 13, 1 mL for one side) once per day in the first 15 days, and once every other day in the rest 2.5 months except weekends. Intramuscular-injection was conducted at the lateral sites of the left or right buttock, 2 mL/time for each site, and the injection frequency was the same to that of the acupoint-injection. The therapeutic effect was assessed according to the standards of Guide Principles for Clinical Research of New Chinese Herbal Drugs (2002) and Asthma Group of Breathing Diseases of China Medical Association (2008). Changes of FEV 1 (forced expiratory volume in the first second)/FVC (forced vital capacity) and PEF% (peak expiratory flow) were detected using a pulmonary function detector. Serum IgA, IgM, IgG and IgE contents were assayed by using an autonomic biochemical analyzer.
  
  
  RESULTS
  After 3 months' treatment, the scores of patients' symptoms and signs and serum IgE and IgG levels were significantly decreased in both muscular-injection and acupoint-injection groups (P<0.01), while asthma controlled test (ACT) scores FEV 1/FVC% and PEF% values were considerably increased in both groups compared to pre-treatment in the same one group (P<0.01). The effects of acupoint-injection were markedly superior to those of the intramuscular-injection in reducing clinical symptom-sign score, and serum IgE content, and in up-regulating ACT score, FEV 1/FVC% and PEF% levels (P<0.05, P<0.01). There were no significant differences in serum IgG, IgA and IgM levels between the two groups 3 months following the treatment (P>0.05).
  
  
  CONCLUSIONS
  Acupoint-injection of BCG polysaccharide nucleic acid can effectively improve bronchial asthma patients' clinical symptoms and sings and pulmonary function, which may be closely associated with its function in down-regulating serum IgE and IgG levels.
authors.forename: Xian
authors.initials: X
authors.lastname: Zou
authors.forename: Jing
authors.initials: J
authors.lastname: Zhu
authors.forename: Xin-zhong
authors.initials: XZ
authors.lastname: Kang
authors.forename: Wei-yong
authors.initials: WY
authors.lastname: Hu
authors.forename: Kang
authors.initials: K
authors.lastname: Wang
authors.forename: Zhong-juan
authors.initials: ZJ
authors.lastname: Peng
authors.forename: Ying
authors.initials: Y
authors.lastname: Fu
authors.forename: Xiao-fei
authors.initials: XF
authors.lastname: Zi
mesh_terms: D015669:Acupuncture Points; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D001407:Bacillus / Q000737:chemistry*; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009696:Nucleic Acids / Q000008:administration & dosage*; D011134:Polysaccharides / Q000008:administration & dosage*; D012129:Respiratory Function Tests; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007070:Immunoglobulin A; D007074:Immunoglobulin G; D009696:Nucleic Acids; D011134:Polysaccharides; D007073:Immunoglobulin E